Who are CM082 combined with everolimus's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cm082-combined-with-everolimus.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CM082 combined with everolimus — Competitive Intelligence Brief

CM082 combined with everolimus (CM082 combined with everolimus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor + mTOR inhibitor combination. Area: Oncology.

phase 3 Tyrosine kinase inhibitor + mTOR inhibitor combination VEGFR, FLT3, mTOR Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CM082 combined with everolimus (CM082 combined with everolimus) — AnewPharma. CM082 is a tyrosine kinase inhibitor that targets multiple kinases including VEGFR and FLT3, combined with everolimus (an mTOR inhibitor) to provide dual pathway inhibition for cancer treatment.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CM082 combined with everolimus TARGET	CM082 combined with everolimus	AnewPharma	phase 3	Tyrosine kinase inhibitor + mTOR inhibitor combination	VEGFR, FLT3, mTOR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor + mTOR inhibitor combination class)

AnewPharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CM082 combined with everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/cm082-combined-with-everolimus. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab